Recruiting
An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition. - IM011-100
Updated: 23 September, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
Inclusion Criteria: - Patients must be willing and able to complete all study-specific procedures and visits - Healthy patients, as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram, and clinical laboratory determinations - Body mass index (BMI) of 18 to 32 kg/m2, inclusive, at screening - Normal renal function at screening Exclusion Criteria: - Any medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease - Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug - History or presence of clinically significant acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicemia) within the 3 months prior to screening - Additional criteria may apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
